Vesugen
Vesugen (Lys-Glu-Asp) is a meticulously engineered Khavinson tripeptide bioregulator designed for extreme vascular intervention. Tasked primarily with restoring the elasticity and functionality of the endothelial lining, it is deployed in aggressive cardiovascular protocols to systematically reverse arterial hardening, halt the progression of atherosclerotic plaque, and profoundly normalize systemic blood flow in aging populations.
Quick Stats
Scientific Data
Mechanism of Action
Vesugen (Lys-Glu-Asp) is a tripeptide bioregulator targeting vascular endothelial cell gene expression. It promotes endothelial function restoration, reduces arterial stiffness, and supports angiogenic signaling. Khavinson studies show improved vascular markers, endothelial function, and cardiovascular biomarkers in aging animals and humans.
Source: PMID: 15677927
Background & History
Vesugen (Lys-Glu-Asp) targets vascular endothelium for eNOS and extracellular matrix maintenance.
Research Use Cases
- ✓Vascular health
- ✓Atherosclerosis prevention
- ✓Endothelial function restoration
Dosing Protocol
| Typical Dose | 10-20 mg/day (oral) or 1-2 mg SC |
| Frequency | 1× daily for 10-30 day cycles |
| Half-Life | ~30 minutes (estimated) |
| Common Vial Sizes | 5 mg, 10 mg |
Dosing Protocols
Khavinson Protocol
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 1000–20000 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 771 mcg | 8100 mcg | 15429 mcg |
| 140 lb(63 kg) | 900 mcg | 9450 mcg | 18000 mcg |
| 160 lb(73 kg) | 1043 mcg | 10950 mcg | 20857 mcg |
| 180 lb(82 kg) | 1171 mcg | 12300 mcg | 23429 mcg |
| 200 lb(91 kg) | 1300 mcg | 13650 mcg | 26000 mcg |
| 220 lb(100 kg) | 1429 mcg | 15000 mcg | 28571 mcg |
| 250 lb(113 kg) | 1614 mcg | 16950 mcg | 32286 mcg |
💉 For exact syringe units based on your vial concentration, use the Vesugen Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Vascular Aging / Endothelial Health
LowVascular endothelial bioregulator. Targets age-suppressed endothelial gene expression.
Reconstitution Example
Safety & Considerations
Research peptide. Extensively used in Russian clinical protocols. Excellent safety profile in elderly populations.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Standard Khavinson protocol.
Synergies & Common Stacks
Vesugen (synthetic) + Ventfort (vascular Cytomax) = comprehensive vascular support.
Vesugen (vessels) + Cardiogen (heart) = comprehensive cardiovascular bioregulator protocol.
Dosing Quick Reference
Frequently Asked Questions
How does Vesugen differ from other cardiovascular peptides?▼
References
- Khavinson VKh et al. “"Short peptide bioregulators for vascular aging".” Bulletin of Experimental Biology and Medicine (2009). PMID: 19503960
📚 Related Articles
Get Vesugen from Vita-Stream — the comprehensive distributor for authentic Khavinson bioregulators. Oral capsules, no injections required.
Affiliate link · Full review